Minor role of the C3a receptor in systemic anaphylaxis in the guinea pig

被引:19
作者
Regal, JF
Klos, A
机构
[1] Univ Minnesota, Dept Pharmacol, Toxicol Grad Program, Duluth, MN 55812 USA
[2] Hannover Med Sch, Inst Med Microbiol, Hannover, Germany
来源
IMMUNOPHARMACOLOGY | 2000年 / 46卷 / 01期
关键词
complement; anaphylatoxin; C3a; anaphylaxis; guinea pig; blood pressure; bronchoconstriction; anaphylactic shock;
D O I
10.1016/S0162-3109(99)00152-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previously, Regal et al. [Regal, J.F., Fraser, D.G., Toth, C.A., 1993. Role of the complement system in antigen-induced bronchoconstriction and changes in blood pressure in the guinea pig. J. Pharmacol. Exp, Ther. 267, 979-988] demonstrated that preventing complement system activation resulted in inhibition of anaphylaxis in the guinea pig, and that the C-terminal 21 amino acids of guinea pig C3a (C3a-peptide) mimic the symptoms of anaphylactic shock in the guinea pig [Regal, J.F., 1997. Role of the complement system in pulmonary disorders. Immunopharmacology 38, 17-25]. To determine if C3a is an essential mediator of systemic anaphylaxis, the anaphylactic response to ovalbumin (OA) was assessed in guinea pigs genetically deficient in the C3a receptor (C3aR(-)) compared to their control strain of animals which were C3a receptor positive (C3aR(+)), In addition, the response to another control strain of animals, Hartley guinea pigs, was determined. Sensitized guinea pigs were anesthetized, and bronchoconstriction and changes in blood pressure were monitored in response to intravenous (i.v.) injection of either C3a-peptide, recombinant human C5a (rHuC5a) or OA. Both Hartley guinea pigs and C3aR(+) animals responded similarly to C3a-peptide and rHuC5a. C3aR- animals, however, were unresponsive to C3a-peptide and responded normally to rHuC5a, confirming their functional deficiency of the C3a receptor. In response to OA, C3aR(+) animals and Hartley guinea pigs responded with a severe bronchoconstriction, an initial transient hypotension, followed by an increase in blood pressure and a delayed prolonged hypotensive response. In contrast, in C3aR- animals, the increased blood pressure response to OA was significantly prolonged, the delayed hypotensive response was blunted, and the bronchoconstriction was delayed compared to the C3aR(+) animals. The difference in the anaphylactic response could not be explained by differing amounts of OA-specific IgG1 antibody or C3a generated during the anaphylactic response. Thus, these data suggest that C3a plays a minor role in the hypotension of systemic anaphylaxis and investigation of a role for other products of complement system activation, either alone or in combination with C3a, is clearly warranted. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:15 / 28
页数:14
相关论文
共 48 条
[31]   COMPLEMENT COMPONENT C3A OR C3A-DESARG AS A NEW MARKER FOR ESTIMATION OF LOCAL VITAL REACTIONS IN INCISED SKIN WOUNDS [J].
MAENO, Y ;
MORI, Y ;
IWASA, M ;
INOUE, H ;
TAKABE, F .
FORENSIC SCIENCE INTERNATIONAL, 1992, 55 (01) :37-44
[32]  
Makrides SC, 1998, PHARMACOL REV, V50, P59
[33]   The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes [J].
Martin, U ;
Bock, D ;
Arseniev, L ;
Tornetta, MA ;
Ames, RS ;
Bautsch, W ;
Kohl, J ;
Ganser, A ;
Klos, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (02) :199-207
[34]   ANAPHYLATOXIN-MEDIATED REGULATION OF THE IMMUNE-RESPONSE .1. C3A-MEDIATED SUPPRESSION OF HUMAN AND MURINE HUMORAL IMMUNE-RESPONSES [J].
MORGAN, EL ;
WEIGLE, WO ;
HUGLI, TE .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (05) :1412-1426
[35]   Requirement and role of C5a in acute lung inflammatory injury in rats [J].
Mulligan, MS ;
Schmid, E ;
BeckSchimmer, B ;
Till, GO ;
Friedl, HP ;
Brauer, RB ;
Hugli, TE ;
Miyasaka, M ;
Warner, RL ;
Johnson, KJ ;
Ward, PA .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (02) :503-512
[36]  
REGAL J F, 1990, Pulmonary Pharmacology, V3, P79, DOI 10.1016/0952-0600(90)90036-I
[37]   Role of the complement system in pulmonary disorders [J].
Regal, JF .
IMMUNOPHARMACOLOGY, 1997, 38 (1-2) :17-25
[38]  
REGAL JF, 1993, J PHARMACOL EXP THER, V267, P979
[39]  
REGAL JF, 1988, J PHARMACOL EXP THER, V246, P542
[40]  
REGAL JF, 1980, J IMMUNOL, V124, P2876